Undisclosed HER3-EGFR bispecific ADC therapeutic
/ SunRock Biopharma, Debiopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 21, 2023
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
(Businesswire)
- "Debiopharm...today announced an exclusive option and license agreement with SunRock Biopharma....The agreement offers Debiopharm licensing options to further develop SunRock’s antibodies integrating Debiopharm’s innovative linker technologies, Multilink™ and AbYlink™, to create innovative antibody drug conjugates (ADCs). Novel ADCs will be developed with capacity to target tumor-specific antigens to fight cancers with high unmet need, including those tumor types expressing HER2/HER3."
Licensing / partnership • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1